These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26345573)

  • 41. VTE and anti-coagulation therapy in cancer patients.
    Miyazaki Y; Sase K; Hasegawa K; Morimoto T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):189-191. PubMed ID: 31378809
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
    Shoji T; Mizugaki H; Ikezawa Y; Furuta M; Takashima Y; Kikuchi H; Goudarzi H; Asahina H; Kikuchi J; Kikuchi E; Sakakibara-Konishi J; Shinagawa N; Tsujino I; Nishimura M
    Intern Med; 2018 Jun; 57(12):1769-1772. PubMed ID: 29434159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
    Yamazaki H; Yagi S; Torii Y; Amano R; Oomichi Y; Sangawa T; Fukuda D; Kadota M; Ise T; Ueno R; Hara T; Kusunose K; Matsuura T; Tobiume T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Akaike M; Sata M
    J Cardiol; 2018 Mar; 71(3):305-309. PubMed ID: 29100817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
    Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
    De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
    Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.
    Unverdorben M; Colonna P; Jin J; Köhler S; Santamaria A; Saxena M; Borrow A; Chen C; von Heymann C; Vanassche T
    Clin Appl Thromb Hemost; 2024; 30():10760296241260728. PubMed ID: 38881370
    [No Abstract]   [Full Text] [Related]  

  • 51. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
    Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venous thromboembolism in multiple myeloma.
    De Stefano V; Za T; Rossi E
    Semin Thromb Hemost; 2014 Apr; 40(3):338-47. PubMed ID: 24599441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
    Minami K; Kumagai K; Sugai Y; Nakamura K; Naito S; Oshima S
    Intern Med; 2018 Jul; 57(14):2025-2028. PubMed ID: 29526957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N; Voorhees PM; Mackman N; Key NS
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
    Plitt A; Giugliano RP
    Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
    [No Abstract]   [Full Text] [Related]  

  • 58. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
    Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
    Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.